• LY2886721 (A8465): Reliable BACE Inhibitor for Alzheimer’s A

  2026-08-03

  This article explores how LY2886721 (SKU A8465), a potent oral BACE inhibitor, addresses common laboratory challenges in amyloid beta reduction and BACE1 enzyme inhibition workflows. Leveraging quantitative data and validated protocols, it provides actionable guidance for experimental design, data interpretation, and product selection in Alzheimer’s disease research.

• CD28-ARS2 Axis Drives PKM Splicing for CD8+ T Cell Antitumor

  2026-08-02

  This study uncovers how CD28-mediated ARS2 upregulation in CD8+ T cells orchestrates alternative splicing of the PKM gene, promoting metabolic flexibility and enhancing antitumor immunity. The findings clarify a novel, PI3K-independent pathway for metabolic reprogramming in T-cell activation, offering new insight into immunometabolic regulation.

• PDI Inhibition Potentiates HDAC Blockade in Myeloma Models

  2026-08-01

  The reference study demonstrates that targeting protein disulfide isomerase (PDI) with LTI6426 significantly enhances the anti-myeloma efficacy of panobinostat, an HDAC inhibitor, even in proteasome inhibitor-resistant contexts. This combination induces pronounced ER stress and may enable lower panobinostat dosing, highlighting a promising, less toxic approach for multiple myeloma therapy.

• CHIR 99021 Trihydrochloride: Pushing Organoid Systems Beyond

  2026-07-31

  Explore how CHIR 99021 trihydrochloride, a potent GSK-3 inhibitor, unlocks controlled modulation of human organoid self-renewal and differentiation. This article reveals advanced, evidence-based strategies for boosting cellular diversity and scalability—delivering insights not found in existing content.

• Toremifene Citrate: 20 Years of Data in Breast Cancer Therap

  2026-07-31

  This review synthesizes two decades of clinical and translational data on Toremifene Citrate as an oral selective estrogen receptor modulator for breast cancer. The findings clarify its efficacy, safety, and unique pharmacological properties, informing personalized endocrine therapy strategies.

• GST-Mediated Resistance in Megalurothrips usitatus: Redox In

  2026-07-30

  This study establishes glutathione S-transferase (GST) as a central mechanism for Megalurothrips usitatus resistance to lambda-cyhalothrin, linking antioxidant defense modulation to pesticide adaptation. By inhibiting GST with diethyl maleate, the research quantifies increased insecticide susceptibility, providing a translational model for resistance management strategies.

• Precision in qPCR: Mechanistic Rigor for Translational Innov

  2026-07-30

  Explore how antibody-mediated hot-start qPCR technology advances gene expression analysis, drawing on new insights from retinal angiogenesis research. This article equips translational researchers with mechanistic context, protocol guidance, and strategic perspectives for deploying APExBIO's HotStart™ 2X Green qPCR Master Mix in high-impact studies.

• Biotin-HPDP: Advanced Strategies for Dynamic Thiol Labeling

  2026-07-29

  Explore how Biotin-HPDP (N-[6-(biotinamido)hexyl]-3’-(2’-pyridyldithio)propionamide) enables dynamic, reversible thiol-specific protein labeling. This in-depth analysis reveals novel assay strategies and insights for neurodegeneration research and beyond.

• Rotigotine's Modulation of Bladder Function in PD Rat Models

  2026-07-29

  This study elucidates how rotigotine, a D1/D2-like dopamine receptor agonist, modulates lower urinary tract function in a 6-OHDA rat model of Parkinson’s disease. The findings clarify dose-dependent effects on micturition reflexes, revealing mechanistic distinctions based on administration route and providing new insight into the compound’s role in addressing non-motor PD symptoms.

• IGF2BP1–THBS1 Axis Drives Macrophage Glycolysis in Pulmonary

  2026-07-28

  The referenced study reveals that IGF2BP1, an m6A reader, enhances pulmonary fibrosis by stabilizing THBS1 mRNA, promoting macrophage M2 polarization and glycolytic metabolism. This mechanistic insight highlights a novel regulatory axis (IGF2BP1/THBS1/TLR4) and identifies potential intervention points for fibrosis research.

• Neuroinflammation Drives TN via CGRP/SP-Piezo2-Ca2+ Axis: In

  2026-07-28

  Liao et al. establish that chronic trigeminal nerve root compression triggers a neuroinflammatory cascade that promotes mechanical allodynia in trigeminal neuralgia through the CGRP/SP-Piezo2 axis and Ca2+-dependent signaling. This work delineates the molecular interplay between neuropeptide signaling, mechanotransduction, and peripheral sensitization, providing a new mechanistic framework for targeted intervention.

• ABT-263 (Navitoclax): Technical Use in Apoptosis Assays

  2026-07-27

  ABT-263 (Navitoclax) is designed for researchers investigating Bcl-2 family-mediated apoptosis in cancer biology, particularly where high-affinity inhibition is critical. It should be used in well-characterized in vitro and in vivo models, not in diagnostic or clinical workflows. Proper storage, solubilization, and workflow validation are essential for reproducible results.

• HotStart™ 2X Green qPCR Master Mix: Practical Workflow Guide

  2026-07-27

  HotStart™ 2X Green qPCR Master Mix addresses the need for high-specificity quantitative PCR in gene expression analysis, nucleic acid quantification, and RNA-seq validation workflows. Its hot-start mechanism minimizes non-specific amplification and primer-dimer artifacts, but it is not formulated for probe-based qPCR or endpoint PCR applications. Researchers should use this master mix where SYBR Green detection and robust specificity are critical.

• Ibuprofen (A8446): Dual COX Inhibition and Cancer Research U

  2026-07-26

  Ibuprofen (2-[4-(2-methylpropyl)phenyl]propanoic acid) is a non-steroidal anti-inflammatory drug with dual COX-1/COX-2 inhibitory activity. It demonstrates anti-proliferative effects in colon cancer models, induces apoptosis, and offers lipid-lowering benefits in animal studies. APExBIO’s Ibuprofen is validated for research use in cell cycle and apoptosis assays.

• MDL 28170: Potent Calpain Inhibitor for Neuroprotection Rese

  2026-07-25

  MDL 28170 is a selective calpain inhibitor with nanomolar potency and high membrane permeability. It demonstrates neuroprotective effects by blocking calpain and cathepsin B activity, as shown in ischemia-reperfusion and neurodevelopmental models. Its rapid blood-brain barrier penetration makes it a benchmark for apoptosis and neuroprotection research.

448 records 9/30 page Previous Next First page 上5页 678910 下5页 Last page